A client with diabetes mellitus type 2 is prescribed linagliptin. The nurse should monitor for which potential adverse effect?

Questions 45

HESI LPN

HESI LPN Test Bank

Pharmacology HESI 2023 Quizlet Questions

Question 1 of 5

A client with diabetes mellitus type 2 is prescribed linagliptin. The nurse should monitor for which potential adverse effect?

Correct Answer: A

Rationale: When a client with diabetes mellitus type 2 is prescribed linagliptin, the nurse should monitor for pancreatitis as a potential adverse effect. Linagliptin has been associated with rare cases of pancreatitis; therefore, monitoring for signs and symptoms of pancreatitis such as severe abdominal pain, nausea, and vomiting is crucial to ensure timely intervention and management.

Question 2 of 5

A client with a history of deep vein thrombosis is prescribed dabigatran. The nurse should monitor for which potential adverse effect?

Correct Answer: A

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.

Question 3 of 5

A client with hypertension is prescribed metoprolol. The healthcare provider should monitor the client for which potential side effect?

Correct Answer: A

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.

Question 4 of 5

A client with chronic kidney disease is prescribed calcium acetate. The nurse should monitor for which potential side effect?

Correct Answer: A

Rationale: When a client with chronic kidney disease is prescribed calcium acetate, the nurse must monitor for hypercalcemia, not hypocalcemia, hyperkalemia, or hypokalemia. Calcium acetate can increase calcium levels in the blood, leading to hypercalcemia. Symptoms of hypercalcemia include fatigue, confusion, constipation, and muscle weakness. Regular monitoring of calcium levels is crucial to prevent complications associated with elevated calcium levels.

Question 5 of 5

A client with rheumatoid arthritis is prescribed tofacitinib. What should the nurse include in the client's teaching plan?

Correct Answer: A

Rationale: Tofacitinib is an immunosuppressive medication used in rheumatoid arthritis. Patients taking tofacitinib should avoid live vaccines because the medication can weaken the immune system, making live vaccines potentially harmful. It is essential to educate the client on this to prevent any complications related to live vaccines during their treatment.

Access More Questions!

HESI LPN Basic


$89/ 30 days

HESI LPN Premium


$150/ 90 days

Similar Questions